Literature DB >> 18458847

Amylase levels in bile in patients with a morphologically normal pancreaticobiliary ductal arrangement.

Jun Horaguchi1, Naotaka Fujita, Yutaka Noda, Go Kobayashi, Kei Ito, Osamu Takasawa, Takashi Obana, Takuro Endo, Kazunari Nakahara, Kazuhiko Ishida, Makoto Yonechi, Dai Hirasawa, Takashi Suzuki, Toshiki Sugawara, Tetuya Ohhira, Kengo Onochi, Yoshihiro Harada.   

Abstract

BACKGROUND: We investigated the presence of occult pancreaticobiliary reflux in patients with a morphologically normal pancreaticobiliary ductal arrangement by measuring biliary amylase levels and compared histopathological findings of the gallbladder between groups with high and low biliary amylase levels.
METHODS: In 178 patients with a normal pancreaticobiliary ductal arrangement who had undergone endoscopic retrograde cholangiopancreatography (ERCP), we sampled bile from the bile duct and measured amylase levels. Then we compared clinical features and histological findings of the gallbladder between high (HALG) and low amylase level groups (LALG).
RESULTS: A high biliary amylase level was observed in 25.8% (46/178) of the patients. The prevalence of a high biliary amylase level was high in patients with gallbladder carcinoma (40%) and in those with choledocholithiasis (28.4%). The level of amylase in bile was high in patients with gallbladder carcinoma, adenomyomatosis of the gallbladder, and chronic cholecystitis. A strong correlation between the levels of amylase and lipase in bile and the dominance of amylase of pancreatic origin in bile were confirmed by isozyme analysis. Thickening of the gallbladder mucosa was a significant manifestation in HALG. Histological examination of the gallbladder mucosa showed that incidences of metaplastic change and atypical epithelium and Ki67-LI in were higher in HALG than in LALG.
CONCLUSIONS: Occult pancreaticobiliary reflux is observed in a considerable number of ERCP candidates. Those who show an extremely high biliary amylase level, at least, may be at high risk for biliary malignancies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18458847     DOI: 10.1007/s00535-008-2158-9

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  14 in total

1.  Precancerous mucosal changes in the gallbladder of patients with occult pancreatobiliary reflux.

Authors:  Jin Kan Sai; Masafumi Suyama; Bunsei Nobukawa; Yoshihiro Kubokawa; Kazuko Yokomizo; Nobuhiro Sato
Journal:  Gastrointest Endosc       Date:  2005-02       Impact factor: 9.427

2.  Amylase activity in human bile.

Authors:  L A Donaldson; S N Joffe; W McIntosh; M J Brodie
Journal:  Gut       Date:  1979-03       Impact factor: 23.059

3.  Periampullary diverticula cause pancreatobiliary reflux.

Authors:  M Sugiyama; Y Atomi
Journal:  Scand J Gastroenterol       Date:  2001-09       Impact factor: 2.423

4.  Histological study of gallbladder and bile duct epithelia in patients with anomalous arrangement of the pancreaticobiliary ductal system: comparison between those with and without a dilated common bile duct.

Authors:  Yutaka Noda; Naotaka Fujita; Go Kobayashi; Kei Ito; Jun Horaguchi; Osamu Takasawa; Takashi Obana; Kazuhiko Ishida; Shigeharu Senoo; Makoto Yonechi; Takashi Suzuki; Dai Hirasawa; Toshiki Sugawara; Masao Kobari; Takashi Sawai; Miwa Uzuki; Mika Watanabe
Journal:  J Gastroenterol       Date:  2007-03-30       Impact factor: 7.527

5.  Histologic and genetic analysis of the gallbladder in patients with occult pancreatobiliary reflux.

Authors:  Takao Itoi; Akihiko Tsuchida; Fumihide Itokawa; Atsushi Sofuni; Toshio Kurihara; Takayoshi Tsuchiya; Fuminori Moriyasu; Kazuhiko Kasuya; Hiromi Serizawa
Journal:  Int J Mol Med       Date:  2005-03       Impact factor: 4.101

6.  Clinical significance of a long common channel.

Authors:  Terumi Kamisawa; Kozue Amemiya; Yuyang Tu; Naoto Egawa; Nobuhiro Sakaki; Kouji Tsuruta; Atsutake Okamoto; Akihiro Munakata
Journal:  Pancreatology       Date:  2002       Impact factor: 3.996

7.  Nationwide survey of cases of choledochal cyst. Analysis of coexistent anomalies, complications and surgical treatment in 645 cases.

Authors:  N Komi; T Tamura; Y Miyoshi; K Kunitomo; H Udaka; H Takehara
Journal:  Surg Gastroenterol       Date:  1984

8.  Carcinoma of the gallbladder with an anomalous connection between the choledochus and the pancreatic duct. Report of 10 cases and review of the literature in Japan.

Authors:  H Kinoshita; E Nagata; K Hirohashi; K Sakai; Y Kobayashi
Journal:  Cancer       Date:  1984-08-15       Impact factor: 6.860

9.  Pathology and cellular kinetics of gallbladder with an anomalous junction of the pancreaticobiliary duct.

Authors:  K Hanada; M Itoh; K Fujii; A Tsuchida; M Hirata; S Ishimaru; T Iwao; N Eguchi; G Kajiyama
Journal:  Am J Gastroenterol       Date:  1996-05       Impact factor: 10.864

10.  Assessment of occult pancreatobiliary reflux in patients with pancreaticobiliary disease by ERCP.

Authors:  Fumihide Itokawa; Takao Itoi; Kazuto Nakamura; Atsushi Sofuni; Kazuhiro Kakimi; Fuminori Moriyasu; Akihiko Tsuchida; Tatsuya Aoki
Journal:  J Gastroenterol       Date:  2004-10       Impact factor: 7.527

View more
  11 in total

1.  Biliary reflux detection in anomalous union of the pancreatico-biliary duct patients.

Authors:  Suk Keu Yeom; Seung Wha Lee; Sang Hoon Cha; Hwan Hoon Chung; Bo Kyung Je; Baek Hyun Kim; Jong Jin Hyun
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 2.  Japanese clinical practice guidelines for pancreaticobiliary maljunction.

Authors:  Terumi Kamisawa; Hisami Ando; Masafumi Suyama; Mitsuo Shimada; Yuji Morine; Hiroshi Shimada
Journal:  J Gastroenterol       Date:  2012-06-22       Impact factor: 7.527

3.  Telomere length of gallbladder epithelium is shortened in patients with congenital biliary dilatation: measurement by quantitative fluorescence in situ hybridization.

Authors:  Yuto Aoki; Junko Aida; Youichi Kawano; Ken-Ichi Nakamura; Naotaka Izumiyama-Shimomura; Naoshi Ishikawa; Tomio Arai; Yoshiharu Nakamura; Nobuhiko Taniai; Eiji Uchida; Kaiyo Takubo; Toshiyuki Ishiwata
Journal:  J Gastroenterol       Date:  2017-11-15       Impact factor: 7.527

Review 4.  Pancreaticobiliary reflux in patients with a normal pancreaticobiliary junction: Pathologic implications.

Authors:  Marcelo A Beltrán
Journal:  World J Gastroenterol       Date:  2011-02-28       Impact factor: 5.742

5.  Pancreaticobiliary reflux in patients with and without cholelithiasis: is it a normal phenomenon?

Authors:  Marcelo A Beltrán; Mario A Contreras; Karina S Cruces
Journal:  World J Surg       Date:  2010-12       Impact factor: 3.352

6.  Pancreaticobiliary reflux as a high-risk factor for biliary malignancy: Clinical features and diagnostic advancements.

Authors:  Reiji Sugita
Journal:  World J Hepatol       Date:  2015-07-08

Review 7.  Magnetic resonance evaluations of biliary malignancy and condition at high-risk for biliary malignancy: Current status.

Authors:  Reiji Sugita
Journal:  World J Hepatol       Date:  2013-12-27

8.  Pancreatobiliary reflux in individuals with a normal pancreaticobiliary junction: a prospective multicenter study.

Authors:  Jun Horaguchi; Naotaka Fujita; Terumi Kamisawa; Goro Honda; Kazuo Chijiiwa; Hiroyuki Maguchi; Masao Tanaka; Mitsuo Shimada; Yoshinori Igarashi; Kazuo Inui; Keiji Hanada; Takao Itoi; Yoshinori Hamada; Tsugumichi Koshinaga; Hideki Fujii; Naoto Urushihara; Hisami Ando
Journal:  J Gastroenterol       Date:  2013-06-05       Impact factor: 7.527

9.  Common bile duct stones associated with pancreatobiliary reflux and disproportionate bile duct dilatation.

Authors:  Cheal Wung Huh; Hee Wook Kim; Seung Woo Yi; Dong Ki Lee; Se Joon Lee
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

10.  Free fatty acids and triglyceride change in the gallbladder bile of gallstone patients with pancreaticobiliary reflux.

Authors:  Yukai Xiang; Xiangyu Kong; Cheng Zhang; Chuanqi He; Jingli Cai; Ruiqi Lu; Bosen Zhang; Liu Lu; Yulong Yang
Journal:  Lipids Health Dis       Date:  2021-08-31       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.